(Q54402147)

English

Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24138302

0 references

Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic? (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24138302

metastatic melanoma

1 reference

based on heuristic

inferred from title

author name string

Jason John Luke

1

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24138302

Patrick Alexander Ott

2

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24138302

language of work or name

0 references

publication date

21 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24138302

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24138302

14

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24138302

18

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24138302

2457-2462

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24138302

Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Profound inhibition of antigen-specific T-cell effector functions by dasatinib

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Targeting immune suppressing myeloid-derived suppressor cells in oncology.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Signaling of c-kit in dendritic cells influences adaptive immunity

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

T cell-signaling network analysis reveals distinct differences between CD28 and CD2 costimulation responses in various subsets and in the MAPK pathway between resting and activated regulatory T cells

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Hepatotoxicity with combination of vemurafenib and ipilimumab

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Integrated T-cell receptor and costimulatory signals determine TGF-β-dependent differentiation and maintenance of Foxp3+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.849244

21 January 2018

Identifiers

10.1517/14656566.2013.849244

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24138302

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24138302

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54402147&oldid=1404722586"